2-butoxy-4-trifluoromethyl-benzaldehyde | 1175134-40-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-butoxy-4-trifluoromethyl-benzaldehyde
• 英文别名: 2-butoxy-4-(trifluoromethyl)benzaldehyde
• CAS: 1175134-40-3
• 化学式: C₁₂H₁₃F₃O₂
• 分子量: 246.229
• InChiKey: MGIFLOGXUGIHHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-butoxy-4-trifluoromethyl-benzaldehyde 、 甲氧羰基亚甲基三苯基正膦 以 乙酸乙酯 为溶剂， 反应 16.0h， 以to yield title compound (464 mg) after column chromatography (Hex/EtOAc=20/1)的产率得到3-(2-butoxy-4-trifluoromethyl-phenyl)-acrylic acid methyl ester
  参考文献：
  名称：

  Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

  摘要：

  本公开涉及新型化合物，其异构体或药学上可接受的盐，作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本公开提供了一种用于预防或治疗疾病的药物组合物，例如疼痛，偏头痛，关节痛，神经痛，神经病，神经损伤，皮肤疾病，膀胱过敏，肠易激综合征，粪便紧迫，呼吸系统疾病，皮肤，眼或黏膜刺激，胃十二指肠溃疡，炎症性疾病，耳病，心脏疾病等等。

  公开号：

  US08557872B2
• 作为产物：
  描述：

  2-butoxy-N-methoxy-N-methyl-4-trifluoromethyl-benzamide 、 Lithium aluminium hydride 以 乙酸乙酯 为溶剂， 反应 1.0h， 以to yield title compound (423 mg) after column chromatography (Hex/EtOAc=20/1)的产率得到2-butoxy-4-trifluoromethyl-benzaldehyde
  参考文献：
  名称：

  Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

  摘要：

  本公开涉及新型化合物，其异构体或药学上可接受的盐，作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本公开提供了一种用于预防或治疗疾病的药物组合物，例如疼痛，偏头痛，关节痛，神经痛，神经病，神经损伤，皮肤疾病，膀胱过敏，肠易激综合征，粪便紧迫，呼吸系统疾病，皮肤，眼或黏膜刺激，胃十二指肠溃疡，炎症性疾病，耳病，心脏疾病等等。

  公开号：

  US08557872B2

文献信息

• [EN] AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME<br/>[FR] DÉRIVÉS AMIDE À TITRE DE LIGANDS DES CANAUX IONIQUES ET COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：RENOVIS INC

  公开号：WO2009064449A1

  公开（公告）日：2009-05-22

  Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  抱歉，我无法直接提供翻译结果。但我可以帮您逐句翻译这段文字。这段文字的意思是：披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤等。
• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Amorepacific Corporation

  公开号：US20140011881A1

  公开（公告）日：2014-01-09

  This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本公开涉及新化合物、其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1；VR1；TRPV1）拮抗剂；以及含有相同化合物的药物组合物。本公开提供了一种用于预防或治疗疾病的药物组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合征、粪便紧急情况、呼吸系统疾病、皮肤、眼睛或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏疾病等等。
• AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Cox Matthew

  公开号：US20110021514A1

  公开（公告）日：2011-01-27

  Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  本文披露了一些化合物，其化学式如下：这些化合物可以制备成药物组合物，并可用于预防和治疗哺乳动物包括人类的各种疾病，例如疼痛、炎症、创伤性损伤等，但不限于此。
• NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS
  申请人：Amorepacific Corporation

  公开号：EP2238105B1

  公开（公告）日：2014-04-16
• NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE
  申请人：UCHIDA Hideharu

  公开号：US20110112071A1

  公开（公告）日：2011-05-12

  A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like; R 2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X 1 represents O, —NR 3 —, or —S(O)r-; X 2 represents a methylene group, O, —NR 3 —, or —S(O)r-; Q′ represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.